SEARCH

SEARCH BY CITATION

References

  • Barisoni, L., Nast, C.C., Jennette, J.C. et al. (2013). Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin. J. Am. Soc. Nephrol. 8, 14491459.
  • Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 68216828.
  • Bergman, P., and Wolchok, J. (2008). Of Mice and Men (and Dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Ther. 6, 817826.
  • Bergman, P.J., Kent, M.S., and Farese, J.P. (2013). Melanoma. In Withrow and MacEwen's Small Animal Clinical Oncology. S.J., Withrow, D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders), pp. 321334.
  • Bogenrieder, T., and Herlyn, M. (2010). The molecular pathology of cutaneous melanoma. Cancer Biomark. 9, 267286.
  • Broekaert, S.M., Roy, R., Okamoto, I. et al. (2010). Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 23, 763770.
  • Buchner, A., and Hansen, L.S. (1987). Pigmented nevi of the oral mucosa: a clinicopathologic study of 36 new cases and review of 155 cases from the literature. Part I: a clinicopathologic study of 36 new cases. Oral Surg. Oral Med. Oral Pathol. 63, 566572.
  • Buery, R.R., Siar, C.H., Katase, N., Gunduz, M., Lefeuvre, M., Fujii, M., Inoue, M., Setsu, K., and Nagatsuka, H. (2011). RAS and BRAF mutation frequency in primary oral mucosal melanoma. Oncol. Rep. 26, 783787.
  • Butler, L.M., Bonnett, B.N., and Page, R.L. (2013). Epidemiology and the evidence-based medicine approach. In Withrow and MacEwen's Small Animal Clinical Oncology. S.J., Withrow, D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders), pp. 6882.
  • Choi, E.W., Shin, I.L., Lee, C.W., and Youn, H.Y. (2008). The effect of gene therapy using CTLA4Ig/silica-nanoparticles on canine experimental autoimmune thyroiditis. J. Gene Med. 10, 795804.
  • Chu, P.Y., Pan, S.L., Liu, C.H., Lee, J., Yeh, L.S., and Liao, A.T. (2012). KIT gene exon 11 mutations in canine malignant melanoma. Vet. J. 196, 226230.
  • Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 21352147.
  • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 23, 43404346.
  • Custer, M.C., Risinger, J.I., Hoover, S., Simpson, R.M., Patterson, T., and Barrett, J.C. (2006). Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor. Prostate 66, 567577.
  • Dai, D.L., Martinka, M., and Li, G. (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 14731482.
  • Damsky, W.E., and Bosenberg, M. (2010). Mouse melanoma models and cell lines. Pigment Cell Melanoma Res. 23, 853859.
  • Davies, M.A., Stemke-Hale, K., Lin, E. et al. (2009). Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 75387546.
  • Ehrhart, N., and Withrow, S. (2013). Biopsy principles. In Withrow and MacEwen's Small Animal Clinical Oncology. S.J., Withrow, D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders), pp. 143148.
  • Esplin, D.G. (2008). Survival of dogs following surgical excision of histologically well-differentiated melanocytic neoplasms of the mucous membranes of the lips and oral cavity. Vet. Pathol. 45, 889896.
  • Fowles, J.S., Denton, C.L., and Gustafson, D.L. (2013). Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Vet. Comp. Oncol. doi: 10.1111/vco.12044. [Epub ahead of print].
  • Garrido, M.C., and Bastian, B.C. (2010). IT as a therapeutic target in melanoma. J. Invest. Dermatol. 130, 2027.
  • Goldschmidt, M., and Hendrick, M. (2002). Tumors of the skin and soft tissues. In Tumors in Domestic Animals. D.J., Meuten, ed. (Ames, IA: Iowa State Press), pp. 7884.
  • Gomes, J., Queiroga, F.L., Prada, J., and Pires, I. (2012). Study of c-kit immunoexpression in canine cutaneous melanocytic tumors. Melanoma Res. 22, 195201.
  • Gordon, I., Paoloni, M., Mazcko, C., and Khanna, C. (2009). The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6, e1000161.
  • Grall, A., Guaguere, E., Planchais, S. et al. (2012). PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nat. Genet. 44, 140147.
  • Graves, S.S., Stone, D., Loretz, C., Peterson, L., McCune, J.S., Mielcarek, M., and Storb, R. (2009). Establishment of long-term tolerance to SRBC in dogs with recombinant canine CTLA4-Ig. Transplantation 15, 317322.
  • Howlader, N., Noone, A.M., Krapcho, M. et al. (eds). (2013). SEER Cancer Statistics Review 1975–2010. (Bethesda, MD: National Cancer Institute). http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013.
  • Kent, M.S., Collins, C.J., and Ye, F. (2009). Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. Am. J. Vet. Res. 70, 263269.
  • Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K., Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian, B.C. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 18781890.
  • Mayr, B., Schaffner, G., Reifinger, M., Zwetkoff, S., and Prodinger, B. (2003). N-ras mutations in canine malignant melanomas. Vet. J. 165, 169171.
  • Mikhail, M., Velazquez, E., Shapiro, R. et al. (2005). PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin. Cancer Res. 11, 51535157.
  • Murakami, A., Mori, T., Sakai, H., Murakami, M., Yanai, T., Hoshino, Y., and Maruo, K. (2011). Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Vet. Comp. Oncol. 9, 219224.
  • Murua Escobar, H., Gunther, K., Richter, A., Soller, J.T., Winkler, S., Nolte, I., and Bullerdiek, J. (2004). Absence of ras-gene hot-spot mutations in canine fibrosarcomas and melanomas. Anticancer Res. 24, 30273028.
  • Newman, S.J., Jankovsky, J.M., Rohrbach, B.W., and Leblanc, A.K. (2012). C-kit expression in canine mucosal melanomas. Vet. Pathol. 49, 760765.
  • Oba, J., Nakahara, T., Abe, T., Hagihara, A., Moroi, Y., and Furue, M. (2011). Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J. Dermatol. Sci. 62, 116123.
  • Omholt, K., Grafstrom, E., Kanter-Lewensohn, L., Hansson, J., and Ragnarsson-Olding, B.K. (2011). KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin. Cancer Res. 17, 39333942.
  • Paoloni, M., and Vail, D. (2013). Clinical trials and developmental therapeutics. In Withrow and MacEwen's Small Animal Clinical Oncology. S.J., Withrow, D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders), pp. 293304.
  • Patel, S.G., Prasad, M.L., Escrig, M., Singh, B., Shaha, A.R., Kraus, D.H., Boyle, J.O., Huvos, A.G., Busam, K., and Shah, J.P. (2002). Primary mucosal malignant melanoma of the head and neck. Head Neck 24, 247257.
  • Pfister, D.G., Ang, K.K., Brizel, D.M. et al. (2012). Mucosal melanoma of the head and neck. J. Natl. Compr. Canc. Netw. 10, 320338.
  • Piliang, M.P. (2011). Acral lentiginous melanoma. Clin. Lab. Med. 31, 281288.
  • Prasad, M.L., Patel, S.G., Huvos, A.G., Shah, J.P., and Busam, K.J. (2004). Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 100, 16571664.
  • Rusk, A., Mckeegan, E., Haviv, F., Majest, S., Henkin, J., and Khanna, C. (2006). Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin. Cancer Res. 12, 74447455.
  • Shearin, A.L., and Ostrander, E.A. (2010). Leading the way: canine models of genomics and disease. Dis. Model Mech. 3, 2734.
  • Shelly, S., Chien, M.B., Yip, B., Kent, M.S., Theon, A.P., Mccallan, J.L., and London, C.A. (2005). Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mamm. Genome 16, 211217.
  • Slipicevic, A., Holm, R., Nguyen, M.T., Bohler, P.J., Davidson, B., and Florenes, V.A. (2005). Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am. J. Clin. Pathol. 124, 528536.
  • Smedley, R.C., Lamoureux, J., Sledge, D.G., and Kiupel, M. (2011a). Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. Vet. Pathol. 48, 3240.
  • Smedley, R.C., Spangler, W.L., Esplin, D.G., Kitchell, B.E., Bergman, P.J., Ho, H.Y., Bergin, I.L., and Kiupel, M. (2011b). Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Vet. Pathol. 48, 5472.
  • Takikita, M., Altekruse, S., Lynch, C.F. et al. (2009). Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 69, 29502955.
  • Tsao, H., Chin, L., Garraway, L.A., and Fisher, D.E. (2012). Melanoma: from mutations to medicine. Genes Dev. 26, 11311155.
  • Ugurel, S., Hildenbrand, R., Zimpfer, A. et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92, 13981405.
  • Walker, G.J., Soyer, H.P., Terzian, T., and Box, N.F. (2011). Modeling melanoma in mice. Pigment Cell Melanoma Res. 24, 11581176.
  • Webster, J.D., Simpson, E.R., Michalowski, A.M., Hoover, S.B., and Simpson, R.M. (2011). Quantifying histological features of cancer biospecimens for biobanking quality assurance using automated morphometric pattern recognition image analysis algorithms. J. Biomol. Tech. 22, 108118.
  • Whiteman, D.C., Pavan, W.J., and Bastian, B.C. (2011). The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24, 879897.
  • Wyman, K., Atkins, M.B., Prieto, V., Eton, O., McDermott, D.F., Hubbard, F., Byrnes, C., Sanders, K., and Sosman, J.A. (2006). Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 20052011.
  • Zhou, X.P., Gimm, O., Hampel, H., Niemann, T., Walker, M.J., and Eng, C. (2000). Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157, 11231128.